| P2093 | author name string | Nicholas P Jewell | |
| | Jasjeet S Sekhon | |
| | Nir Eyal | |
| | Mark Budolfson | |
| | Alexander Guerrero | |
| | David Broockman | |
| | Joshua Kalla | |
| | Monica Magalhaes | |
| P2860 | cites work | Cognitive load selectively interferes with utilitarian moral judgment. | Q30482331 |
| | Assessing the public's views in research ethics controversies: deliberative democracy and bioethics as natural allies | Q33786044 |
| | Addressing the vaccine confidence gap. | Q34191703 |
| | Institutional review board community members: who are they, what do they do, and whom do they represent? | Q36546855 |
| | Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development | Q58699135 |
| | Generalizability of heterogeneous treatment effect estimates across samples | Q60998031 |
| | Universals and variations in moral decisions made in 42 countries by 70,000 participants | Q83388529 |
| | A National Survey Reveals Public Skepticism About Research-Based Treatment Guidelines | Q85156642 |
| | What risks should be permissible in controlled human infection model studies? | Q89961251 |
| | Human challenge studies to accelerate coronavirus vaccine licensure | Q90784765 |
| | Estimates of the severity of coronavirus disease 2019: a model-based analysis | Q91511312 |
| | Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: Implications for future vaccines | Q92019217 |
| | Ethics of controlled human infection to study COVID-19 | Q94547788 |
| | A strategic approach to COVID-19 vaccine R&D | Q94560952 |
| | Estimating the burden of SARS-CoV-2 in France | Q95628403 |
| | Ethical guidelines for deliberately infecting volunteers with COVID-19 | Q95930903 |
| | COVID-19 human challenge studies: ethical issues | Q96033598 |
| | Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models | Q96945726 |
| | Exploring the acceptability of controlled human infection with SARSCoV2-a public consultation | Q97415473 |
| | Why continuing uncertainties are no reason to postpone challenge trials for coronavirus vaccines | Q97526915 |
| | Unnecessary hesitancy on human vaccine tests-Response | Q97535753 |
| | Why we (probably) must deliberately infect | Q98164923 |
| P921 | main subject | COVID-19 | Q84263196 |
| | COVID-19 vaccine | Q87719492 |
| P577 | publication date | 2020-12-14 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Broad cross-national public support for accelerated COVID-19 vaccine trial designs | |